The Service of the Commission for the Protection of Competition has received a notification of a concentration, according to Section 10 of the Control of Concentrations between Enterprises Law of 2014, concerning the acquisition of a part of share capital of D.Med Consulting GmbH by Fresenius Medical Care AG & Co. KGaA through its wholly owned subsidiary, Fresenius Medical Care Beteiligungsgesellschaft mbH, Bad Homburg v.d.H., Germany.
Fresenius Medical Care Beteiligungsgesellschaft mbH, Bad Homburg v.d.H. is a limited liability company incorporated under the laws of Germany and is a member of the Fresenius Medical Care Group. The said Group is active in the provision of products and medical services, primarily for individuals undergoing dialysis as a result of chronic kidney disease and patients suffering from acute kidney failure.
D.Med Consulting GmbH is the target in this transaction and is incorporated under the laws of Germany. The said company is active in the field of development and marketing of as well as consulting regarding medical products with a focus on dialysis technologies and related medical fields. This company belongs to the KR ² GmbH which will remain as a shareholder in D.Med Consulting GmbH.
ΚR² GmbH is a limited liability company incorporated under the laws of Germany. The said company is a global medical service and product provider with focus on renal and diabetes care.